- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Enrollment closed, Metastases: Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 24, 2024
P2, N=60, Active, not recruiting,
Recruiting --> Active, not recruiting
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival (Chapin Theater - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_7817;
Addition of Salmonella-IL2 to FOLFIRINOX for stage 4 metastatic pancreatic cancer results in the near doubling of median survival when compared to historical and site-specific controls receiving FOLFIRNOX only. These findings strongly indicate that a larger pivotal phase 3 multicenter trial is warranted.
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Salspera (Theater 3) - Jun 4, 2022 - Abstract #BIO2022BIO_76;
With a median life expectancy of just 11 months, this patient is now in month 36 post-diagnosis, is feeling extremely well with complete resolution of her pulmonary metastases and significant diminution of her liver metastases and primary pancreatic cancer. A Phase II clinical study of Saltikva in metastatic pancreatic cancer is currently ongoing.
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Clinical, Journal: A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers. (Pubmed Central) - Sep 4, 2021
Therefore, we tested a unique cancer treatment strategy comprised of oral delivery of Saltikva, an attenuated strain of Salmonella typhimurium that contain the human gene for interleukin-2...All patients had progressive disease and eventually succumbed to their illness. Although no survival advantage was seen in this single dose study, the statistically significant increase in circulating NK and NK-T cell demonstrates an immunologic effect from this treatment regimen and suggest that a multiple dose study should be undertaken.
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
[VIRTUAL] Salspera, LLC () - Apr 3, 2021 - Abstract #BIO2021BIO_115;
P2
With a median life expectancy of just 11 months, this patient is now in month 30 post-diagnosis and is feeling extremely well with complete resolution of her pulmonary metastases and significant diminution of her liver metastases and primary pancreatic cancer. A Phase II clinical study of Saltikva in metastatic pancreatic cancer is currently ongoing (NCT04589234).
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
[VIRTUAL] Microbial based immunotherapy: Saltikva as a novel therapeutic for solid tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_1299;
P2
With a median life expectancy of just 11 months, this patient is now in month 24 post-diagnosis, is feeling extremely well with complete resolution of her pulmonary metastases and significant diminution of her liver metastases and primary pancreatic cancer. A Phase II clinical study of Saltikva in metastatic pancreatic cancer is currently ongoing (NCT04589234).
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Enrollment open, Metastases: Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 27, 2020
P2, N=60, Recruiting,
A Phase II clinical study of Saltikva in metastatic pancreatic cancer is currently ongoing (NCT04589234). Not yet recruiting --> Recruiting
- |||||||||| Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
New P2 trial, Metastases: Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 19, 2020
P2, N=60, Not yet recruiting,
|
